AGL · XBRL financial data
agilon health financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (AGL's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 816* | 1,604 | 1,483 | 1,451 | 1,522* | 1,533 | 1,395 | 1,435 | 1,569* | 1,420 | 1,495 | 1,519 |
| General and administrative | 63* | 76 | 70 | 63 | 60* | 66 | 56 | 56 | 60* | 54 | 89 | 67 |
| Operating income (loss) | (160)* | (7) | (43) | (134) | (108)* | (22) | (116) | (131) | (194)* | 4 | 12 | 24 |
| Interest expense | 2* | 1 | 2 | 2 | 2* | 2 | 2 | 2 | 2* | 2 | 2 | 2 |
| Income tax expense (benefit) | 0* | (0) | 0 | (1) | 2* | 0 | 0 | (0) | 1* | 0 | (0) | 4 |
| Net income (loss) | (230)* | (6) | (31) | (118) | (106)* | 12 | (104) | (110) | (189)* | 49 | 18 | 35 |
| Earnings per share, basic‡ USD per share | (14.25)* | — | — | — | (6.50)* | 0.73 | (6.31) | (6.65) | (11.50)* | 2.95 | 1.07 | 2.08 |
| Earnings per share, diluted‡ USD per share | (14.75)* | — | — | — | (6.50)* | 0.73 | (6.31) | (6.65) | (11.50)* | 2.94 | 1.04 | 1.97 |
| Weighted average shares, basic‡ millions of shares | 16* | 16 | 16 | 16 | 16* | 17 | 17 | 17 | 17* | 17 | 17 | 17 |
| Weighted average shares, diluted‡ millions of shares | 16* | 17 | 16 | 16 | 16* | 17 | 17 | 17 | 17* | 17 | 17 | 18 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2026); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal quarters (AGL's year ends in late December)
- ‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (March 2026); filings made before it reported them unadjusted.
Cash flows
CSVFiscal quarters (AGL's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (230)* | (6) | (31) | (118) | (106)* | 12 | (104) | (110) | (189)* | 49 | 18 | 35 |
| Stock-based compensation | 16* | 17 | 18* | 13* | 2* | 17 | 15* | 7* | 10* | 6 | 24* | 19* |
| Depreciation and amortization | 5* | 6 | 6* | 6* | 6* | 7 | 7* | 7* | 7* | 7 | 7* | 7* |
| Net cash from operating activities | (61)* | (48) | (19)* | (8)* | 16* | (32) | (35)* | (18)* | (21)* | 24 | (57)* | 50* |
| Purchases of property and equipment | 4* | 3 | 3* | 4* | 3* | 4 | 3* | 3* | 3* | 3 | 3* | 3* |
| Net cash from investing activities | (2)* | 51 | 18* | 47* | 24* | (23) | 70* | 19* | 23* | 19 | 20* | 18* |
| Proceeds from issuing common stock | 0* | 2 | (0)* | (0)* | (0)* | (0) | — | — | — | — | — | — |
| Proceeds from issuing equity | year only | — | — | — | year only | — | — | — | year only | — | — | — |
| Share repurchases | 0* | — | — | 0* | — | — | — | — | — | — | — | — |
| Proceeds from long-term debt | year only | — | — | — | — | — | — | — | — | — | — | — |
| Repayments of long-term debt | 1* | 1 | 1* | 1* | 0* | 0 | 0* | 0* | 0* | 4 | 0* | 0* |
| Net cash from financing activities | (1)* | 1 | (2)* | (1)* | (0)* | (0) | (3)* | (0)* | (0)* | (5) | 5* | (0)* |
| Net change in cash | (64)* | 4 | (2)* | 37* | 40* | (55) | 33* | 0* | 2* | 38 | (33)* | 68* |
Compare with peers
SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| agilon health | 174 | 1,519 | 50* | 16.8M | 10-QSep 30, 2026 |
| Sotera Health | 412 | 325 | 111* | 285.6M | 10-QSep 30, 2026 |
| Progyny | 153 | 351 | 50* | 76.7M | 10-QJun 30, 2026 |
| Acadia Healthcare Company | 163 | 895 | 98* | 93.0M | 10-QSep 30, 2026 |
| Viemed Healthcare | 9.7 | 81 | 11* | 37.9M | 10-QSep 30, 2026 |
| Concentra Group Holdings Parent | 158 | 606 | 135* | 127.5M | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
